Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Clean Energy Technologies, Inc. (“CETY”) (Nasdaq: CETY), a clean energy manufacturing and services company offering ...

A battery manufacturer has selected Kentucky for a nearly $712 million project to produce industrial-sized batteries used to ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Dare Bioscience (DARE) delivered earnings and revenue surprises of 8.33% and 98.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

“I think the reality is we are probably in one of the biggest periods of geopolitical uncertainty and instability we have seen in our lifetimes,” Brian Schimpf, co-founder and CEO of defense tech ...

When retirement is nearing, you need to get your finances in order. If you weren't already, now is the time to get laser ...

Medline, a market-leading manufacturer and supplier of medical supplies and solutions, has been named one of the winners of ...

According to a recall report, issued by the National Highway Traffic Safety Administration, the problem may affect 2,431 ...

CoinDesk Indices presents its daily market update, highlighting the performance of leaders and laggards in the CoinDesk 20 ...

Soccer player George Boyd made over 100 Premier League appearances and has now joined crypto ETF issuer Jacobi Asset ...